Pharma News

Pfizer has agreed to pay $290,000 to patients in Colorado, Vermont, Arizona and Kansas to settle allegations over alleged misleading copay coupons for four drugs. ...

SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced that the U.S. Food and Drug Administration (FDA) approved the int...

US scientists have begun a trial on a vaccine that will shield individuals from developing pancreatic cancer.

Pain and need for opiate painkillers among cancer patients may be reduced by medicinal cannabis as per a study published in Frontiers in Pain Research.

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two ...

Sanofi’s Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring ...

AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to contr...

Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China’s Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. ...

AbbVie has secured options to worldwide rights for several of Cugene’s interleukin-2 (IL-2) muteins, which are proteins with altered amino acid sequences that are being evaluated as potential tre...

The World Health Organization (WHO) has granted an emergency use listing (EUL) for CanSino Biologics’ (CanSinoBIO) recombinant novel Covid-19 vaccine, Convidecia. ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s Vabysmo (faricimab) for treatment of wet age-related macular degeneration and diabetic macular edema-re...

Ascentage Pharma has reported that its drug, olverembatinib (HQP1351), demonstrated a therapeutic potential to hinder SARS-CoV-2 omicron-mediated cytokine release in a preclinical study. ...